ALX ONCOLOGY HOLDINGS INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Find out what a historical investment in ALX ONCOLOGY HOLDINGS INC would be worth today using our ALXO stock calculator.
$74.28M
-
0.00%
40
$1.40
$1.30
$0.00
$2.27
$0.40
Ready to start your investing journey with Stake?
Open an accountALXO FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ALXO
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in ALXO
on Stake
Buy ALXO from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of ALXO from only US$10 with fractional shares
